Cancer-associated fibroblasts in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 22, Issue 30, 2016, Pages 6841-6850

  Kubo, Norio ^a   Araki, Kenichiro ^a   Kuwano, Hiroyuki ^a   Shirabe, Ken ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Cancer associated fibroblast; Hepatic stellate cell; Hepatocellular carcinoma; Immunosuppression; Therapeutic target

Indexed keywords

ANTIFIBROTIC AGENT; ARMEPAVINE; BENZODIAZEPINE; CONOPHYLLINE; CURCUMIN; FOLLISTATIN; GLIOTOXIN; INTERLEUKIN 6; LINIFANIB; LYSOPHOSPHATIDIC ACID; MATRIX METALLOPROTEINASE; PLASMIN; PLATELET DERIVED GROWTH FACTOR; PRI 724; PROGRAMMED DEATH 1 LIGAND 1; SALAZOSULFAPYRIDINE; SALVIANOLIC ACID; STAT3 PROTEIN; SUNITINIB; TANSHINONE I; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; URSOLIC ACID;

ANGIOGENESIS; CANCER ASSOCIATED FIBROBLAST; CARCINOGENESIS; FIBROBLAST; HUMAN; IMMUNOMODULATION; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; LIVER FIBROSIS; MOLECULAR INTERACTION; NONHUMAN; REVIEW; THERAPY RESISTANCE; TUMOR ASSOCIATED LEUKOCYTE; CARCINOMA, HEPATOCELLULAR; CELL COMMUNICATION; HEPATIC STELLATE CELL; LIVER NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

CANCER-ASSOCIATED FIBROBLASTS; CARCINOMA, HEPATOCELLULAR; CELL COMMUNICATION; HEPATIC STELLATE CELLS; HUMANS; LIVER NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84982162814     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i30.6841     Document Type: Review

References (134)

1. Thompson AI, Conroy KP, Henderson NC. Hepatic stellate cells: Central modulators of hepatic carcinogenesis. BMC Gastroenterol 2015; 15: 63 [PMID: 26013123 DOI: 10.1186/s12876-015-0291-5]
2. Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth. Cancers (Basel) 2015; 7: 2443-2458 [PMID: 26690480 DOI: 10.3390/cancers7040902]
3. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123: 2229-2238 [PMID: 18777559 DOI: 10.1002/ijc.23925]
4. Sukowati CH, Anfuso B, Crocé LS, Tiribelli C. The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis. BMC Cancer 2015; 15: 188 [PMID: 25879842 DOI: 10.1186/s12885-015-1196-y]
5. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349-363 [PMID: 11988769 DOI: 10.1038/nrm809]
6. Terada T, Makimoto K, Terayama N, Suzuki Y, Nakanuma Y. Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. J Hepatol 1996; 24: 706-712 [PMID: 8835746]
7. Yamamura Y, Asai N, Enomoto A, Kato T, Mii S, Kondo Y, Ushida K, Niimi K, Tsunoda N, Nagino M, Ichihara S, Furukawa K, Maeda K, Murohara T, Takahashi M. Akt-Girdin signaling in cancerassociated fibroblasts contributes to tumor progression. Cancer Res 2015; 75: 813-823 [PMID: 25732845 DOI: 10.1158/0008-5472. CAN-14-1317]
8. Song J, Ge Z, Yang X, Luo Q, Wang C, You H, Ge T, Deng Y, Lin H, Cui Y, Chu W, Yao M, Zhang Z, Gu J, Fan J, Qin W. Hepatic stellate cells activated by acidic tumor microenvironment promote the metastasis of hepatocellular carcinoma via osteopontin. Cancer Lett 2015; 356: 713-720 [PMID: 25449435 DOI: 10.1016/j.canlet.2014.10.021]
9. Eyden B. The myofibroblast: Phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J Cell Mol Med 2008; 12: 22-37 [PMID: 18182061 DOI: 10.1111/j.1582-4934.2007.00213.x]
10. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200: 429-447 [PMID: 12845611 DOI: 10.1002/path.1398]
11. El Taghdouini A, Sørensen AL, Reiner AH, Coll M, Verhulst S, Mannaerts I, Øie CI, Smedsrød B, Najimi M, Sokal E, Luttun A, Sancho-Bru P, Collas P, van Grunsven LA. Genome-wide analysis of DNA methylation and gene expression patterns in purified, uncultured human liver cells and activated hepatic stellate cells. Oncotarget 2015; 6: 26729-26745 [PMID: 26353929 DOI: 10.18632/oncotarget.4925]
12. Martin M, Ancey PB, Cros MP, Durand G, Le Calvez-Kelm F, Hernandez-Vargas H, Herceg Z. Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-ß) is associated with a DNA methylome switch. BMC Genomics 2014; 15: 435 [PMID: 24898317 DOI: 10.1186/1471-216 4-15-435]
13. Vázquez-Villa F, García-Ocaña M, Galván JA, García-Martínez J, García-Pravia C, Menéndez-Rodríguez P, González-del Rey C, Barneo-Serra L, de Los Toyos JR. COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression. Tumour Biol 2015; 36: 2213-2222 [PMID: 25761876 DOI: 10.1007/s13277-015-3295-4]
14. Littlepage LE, Egeblad M, Werb Z. Coevolution of cancer and stromal cellular responses. Cancer Cell 2005; 7: 499-500 [PMID: 15950897 DOI: 10.1016/j.ccr.2005.05.019]
15. Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015; 121: 2874-2882 [PMID: 26079399 DOI: 10.1002/cncr.29528]
16. Hendriks HF, Verhoofstad WA, Brouwer A, de Leeuw AM, Knook DL. Perisinusoidal fat-storing cells are the main vitamin A storage sites in rat liver. Exp Cell Res 1985; 160: 138-149 [PMID: 4043241]
17. Asahina K, Tsai SY, Li P, Ishii M, Maxson RE, Sucov HM, Tsukamoto H. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology 2009; 49: 998-1011 [PMID: 19085956 DOI: 10.1002/hep.22721]
18. Henderson NC, Iredale JP. Liver fibrosis: Cellular mechanisms of progression and resolution. Clin Sci (Lond) 2007; 112: 265-280 [PMID: 17261089 DOI: 10.1042/CS20060242]
19. Friedman SL. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007]
20. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-337 [PMID: 15549095 DOI: 10.1038/nature03096]
21. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-5011 [PMID: 10519415]
22. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218 [PMID: 15690074 DOI: 10.1172/JCI24282]
23. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998; 280: 1036-1037 [PMID: 9616081]
24. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003; 107: 1-10 [PMID: 12925950 DOI: 10.1002/ijc.11335]
25. Török NJ. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol 2008; 43: 315-321 [PMID: 18592147 DOI: 10.1007/s00535-008-2181-x]
26. Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009; 36: 4-12 [PMID: 18600481 DOI: 10.1007/s12016-008-8091-0]
27. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10 Suppl 1: S59-S67 [PMID: 12655347 DOI: 10.1038/sj.cdd.4401163]
28. Brenner DA, Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E, Yamauchi M, Gillan A, Rippe RA. New aspects of hepatic fibrosis. J Hepatol 2000; 32: 32-38 [PMID: 10728792]
29. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-S181 [PMID: 16447285 DOI: 10.1002/hep.20956]
30. Li C, Deng M, Hu J, Li X, Chen L, Ju Y, Hao J, Meng S. Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget 2016; 7: 17021-17034 [PMID: 26933995 DOI: 10.18632/oncotarget.7740]
31. Wallace MC, Friedman SL. Hepatic fibrosis and the microenvironment: Fertile soil for hepatocellular carcinoma development. Gene Expr 2014; 16: 77-84 [PMID: 24801168 DOI: 10.3727/105221614X13919976902057]
32. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
33. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736 (11)61347-0]
34. Dotto GP. Multifocal epithelial tumors and field cancerization: Stroma as a primary determinant. J Clin Invest 2014; 124: 1446-1453 [PMID: 24691479 DOI: 10.1172/JCI72589]
35. Hu M, Yao J, Cai L, Bachman KE, van den Brûle F, Velculescu V, Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005; 37: 899-905 [PMID: 16007089 DOI: 10.1038/ng1596]
36. Jiang L, Gonda TA, Gamble MV, Salas M, Seshan V, Tu S, Twaddell WS, Hegyi P, Lazar G, Steele I, Varro A, Wang TC, Tycko B. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res 2008; 68: 9900-9908 [PMID: 19047171 DOI: 10.1158/0008-5472.CAN-08-1319]
37. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123: 1001-1011 [PMID: 16360031 DOI: 10.1016/j.cell.2005.09.030]
38. Lin ZY, Chuang WL. Hepatocellular carcinoma cells cause different responses in expressions of cancer-promoting genes in different cancer-associated fibroblasts. Kaohsiung J Med Sci 2013; 29: 312-318 [PMID: 23684136 DOI: 10.1016/j.kjms.2012.08.012]
39. Kim GJ, Rhee H, Yoo JE, Ko JE, Lee JS, Kim H, Choi JS, Park YN. Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior. PLoS One 2014; 9: E105094 [PMID: 25126747 DOI: 10.1371/journal.pone.0105094]
40. Eiró N, Vizoso FJ. Importance of tumor/stroma interactions in prognosis of hepatocellular carcinoma. Hepatobiliary Surg Nutr 2014; 3: 98-101 [PMID: 24812604 DOI: 10.3978/j.issn.2304-3881.2 014.02.12]
41. Mazzocca A, Dituri F, Lupo L, Quaranta M, Antonaci S, Giannelli G. Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology 2011; 54: 920-930 [PMID: 21674557 DOI: 10.1002/hep.24485]
42. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348 [PMID: 15882617 DOI: 10.1016/j.cell.2005.02.034]
43. Zheng K, Li HY, Su XL, Wang XY, Tian T, Li F, Ren GS. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29: 31 [PMID: 20380740 DOI: 10.1186/1756-9966-29-31]
44. Song T, Dou C, Jia Y, Tu K, Zheng X. TIMP-1 activated carcinoma- Associated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma. Oncotarget 2015; 6: 12061-12079 [PMID: 25909286 DOI: 10.18632/oncotarget.3616]
45. Teng F, Tian WY, Wang YM, Zhang YF, Guo F, Zhao J, Gao C, Xue FX. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol 2016; 9: 8 [PMID: 26851944 DOI: 10.1186/s13045-015-0231-4]
46. Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff AK, Hellerbrand C. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009; 100: 646-653 [PMID: 19175606 DOI: 10.1111/j.1349-7006.2009.01087.x]
47. Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K, Yano S. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol 2011; 179: 1483-1493 [PMID: 21763682 DOI: 10.1016/j.ajpath.2011.05.060]
48. Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang GY, Li TJ, Li X, Wu XY, Tai Y, Zhou J, Chen GH, Zhang Q. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One 2013; 8: E63243 [PMID: 23667593 DOI: 10.1371/journal.pone.0063243]
49. Yan XL, Fu CJ, Chen L, Qin JH, Zeng Q, Yuan HF, Nan X, Chen HX, Zhou JN, Lin YL, Zhang XM, Yu CZ, Yue W, Pei XT. Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway. Breast Cancer Res Treat 2012; 132: 153-164 [PMID: 21584665 DOI: 10.1007/s10549-011-1577-0]
50. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4: E4992 [PMID: 19352430 DOI: 10.1371/journal.pone.0004992]
51. Giulianelli S, Cerliani JP, Lamb CA, Fabris VT, Bottino MC, Gorostiaga MA, Novaro V, Góngora A, Baldi A, Molinolo A, Lanari C. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer 2008; 123: 2518-2531 [PMID: 18767044 DOI: 10.1002/ijc.23802]
52. Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, Chen J, Dai Y, Li Y, Kong KL, Kwong DL, Guan XY. Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/ß-catenin signalling pathway. Gut 2011; 60: 1635-1643 [PMID: 21672941 DOI: 10.1136/gut.2011.241638]
53. Saito RA, Micke P, Paulsson J, Augsten M, Peña C, Jönsson P, Botling J, Edlund K, Johansson L, Carlsson P, Jirström K, Miyazono K, Ostman A. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res 2010; 70: 2644-2654 [PMID: 20233876 DOI: 10.1158/0008-5472. CAN-09-3644]
54. Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N, Rotter V. Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Mol Cancer Res 2009; 7: 1212-1223 [PMID: 19671672 DOI: 10.1158/1541-7786.MCR-09-0073]
55. Lin ZY, Chuang YH, Chuang WL. Cancer-associated fibroblasts upregulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. Biomed Pharmacother 2012; 66: 525-529 [PMID: 22739041 DOI: 10.1016/j.biopha.2012.02.001]
56. Liu F, Zhang W, Yang F, Feng T, Zhou M, Yu Y, Yu X, Zhao W, Yi F, Tang W, Lu Y. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep 2016; 6: 21260 [PMID: 26879559 DOI: 10.1038/srep21260]
57. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401 [PMID: 16572188 DOI: 10.1038/nrc1877]
58. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) 2010; 15: 166-179 [PMID: 20036813]
59. Guirouilh J, Castroviejo M, Balabaud C, Desmouliere A, Rosenbaum J. Hepatocarcinoma cells stimulate hepatocyte growth factor secretion in human liver myofibroblasts. Int J Oncol 2000; 17: 777-781 [PMID: 10995891]
60. Guirouilh J, Le Bail B, Boussarie L, Balabaud C, Bioulac-Sage P, Desmoulière A, Schuppan D, Rosenbaum J. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J Hepatol 2001; 34: 78-83 [PMID: 11211911]
61. Efimova EA, Glanemann M, Liu L, Schumacher G, Settmacher U, Jonas S, Langrehr JM, Neuhaus P, Nüssler AK. Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines. Eur Surg Res 2004; 36: 300-307 [PMID: 15359093 DOI: 10.1159/000079915]
62. Monvoisin A, Neaud V, De Lédinghen V, Dubuisson L, Balabaud C, Bioulac-Sage P, Desmoulière A, Rosenbaum J. Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J Hepatol 1999; 30: 511-518 [PMID: 10190737]
63. Suzuki A, Hayashida M, Kawano H, Sugimoto K, Nakano T, Shiraki K. Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology 2000; 32: 796-802 [PMID: 11003625 DOI: 10.1053/jhep.2000.17738]
64. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995; 373: 699-702 [PMID: 7854452 DOI: 10.1038/373699a0]
65. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2: 315-324 [PMID: 16264989 DOI: 10.1038/ncponc0195]
66. Meyer DH, Bachem MG, Gressner AM. Modulation of hepatic lipocyte proteoglycan synthesis and proliferation by Kupffer cellderived transforming growth factors type beta 1 and type alpha. Biochem Biophys Res Commun 1990; 171: 1122-1129 [PMID: 1699522]
67. Roth S, Schurek J, Gressner AM. Expression and release of the latent transforming growth factor beta binding protein by hepatocytes from rat liver. Hepatology 1997; 25: 1398-1405 [PMID: 9185759 DOI: 10.1002/hep.510250616]
68. Giannelli G, Villa E, Lahn M. Transforming growth factor-ß as a therapeutic target in hepatocellular carcinoma. Cancer Res 2014; 74: 1890-1894 [PMID: 24638984 DOI: 10.1158/0008-5472. CAN-14-0243]
69. Wright JH, Johnson MM, Shimizu-Albergine M, Bauer RL, Hayes BJ, Surapisitchat J, Hudkins KL, Riehle KJ, Johnson SC, Yeh MM, Bammler TK, Beyer RP, Gilbertson DG, Alpers CE, Fausto N, Campbell JS. Paracrine activation of hepatic stellate cells in plateletderived growth factor C transgenic mice: Evidence for stromal induction of hepatocellular carcinoma. Int J Cancer 2014; 134: 778-788 [PMID: 23929039 DOI: 10.1002/ijc.28421]
70. van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H, Mikulits W. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009; 28: 4022-4033 [PMID: 19718050 DOI: 10.1038/onc.2009.253]
71. Ding S, Chen G, Zhang W, Xing C, Xu X, Xie H, Lu A, Chen K, Guo H, Ren Z, Zheng S, Zhou L. MRC-5 fibroblast-conditioned medium influences multiple pathways regulating invasion, migration, proliferation, and apoptosis in hepatocellular carcinoma. J Transl Med 2015; 13: 237 [PMID: 26198300 DOI: 10.1186/s12967-015-0588-8]
72. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-591 [PMID: 12894246 DOI: 10.1038/nrc1143]
73. Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, Han JW, Kim JM, Lee JS, Kang J, Park CG, Mills GB, Lee HY. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 2011; 30: 1351-1359 [PMID: 21102517 DOI: 10.1038/onc.2010.517]
74. Wang DS, Dou KF, Li KZ, Song ZS. Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway. World J Gastroenterol 2004; 10: 299-302 [PMID: 14716844 DOI: 10.3748/WJG.v10.i2.299]
75. Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhau HE, von Eschenbach AC, Chung LW. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 1990; 87: 75-79 [PMID: 2296606]
76. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 2010; 17: 135-147 [PMID: 20138012 DOI: 10.1016/j.ccr.2009.12.041]
77. Albrengues J, Bourget I, Pons C, Butet V, Hofman P, Tartare- Deckert S, Feral CC, Meneguzzi G, Gaggioli C. LIF mediates proinvasive activation of stromal fibroblasts in cancer. Cell Rep 2014; 7: 1664-1678 [PMID: 24857661 DOI: 10.1016/j.celrep.2014.04.036]
78. Satoyoshi R, Kuriyama S, Aiba N, Yashiro M, Tanaka M. Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts. Oncogene 2015; 34: 650-660 [PMID: 24441039 DOI: 10.1038/onc.2013.584]
79. Albrengues J, Bertero T, Grasset E, Bonan S, Maiel M, Bourget I, Philippe C, Herraiz Serrano C, Benamar S, Croce O, Sanz-Moreno V, Meneguzzi G, Feral CC, Cristofari G, Gaggioli C. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancerassociated fibroblasts. Nat Commun 2015; 6: 10204 [PMID: 26667266 DOI: 10.1038/ncomms10204]
80. Gopalakrishnan S, Van Emburgh BO, Robertson KD. DNA methylation in development and human disease. Mutat Res 2008; 647: 30-38 [PMID: 18778722 DOI: 10.1016/j.mrfmmm.2008.08.006]
81. Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski WW, Swartz MA, Brisken C, Lefort K, Dotto GP. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol 2015; 17: 1193-1204 [PMID: 26302407 DOI: 10.1038/ncb3228]
82. Procopio MG, Laszlo C, Dotto GP. CSL-p53: From senescence to CAF activation. Cell Cycle 2016; 15: 485-486 [PMID: 26735629 DOI: 10.1080/15384101.2015.1130091]
83. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: From mechanisms to therapy. Nat Med 2015; 21: 1424-1435 [PMID: 26646499 DOI: 10.1038/nm.4000]
84. Sprinzl MF, Galle PR. Immune control in hepatocellular carcinoma development and progression: Role of stromal cells. Semin Liver Dis 2014; 34: 376-388 [PMID: 25369300 DOI: 10.1055/s-0034-1394138]
85. Zhang HH, Mei MH, Fei R, Liu F, Wang JH, Liao WJ, Qin LL, Wei L, Chen HS. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat 2010; 17 Suppl 1: 34-43 [PMID: 20586932 DOI: 10.1111/j.1365-2893.2010.01269.x]
86. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206: 1327-1337 [PMID: 19451266 DOI: 10.1084/jem.20082173]
87. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54: 948-955 [PMID: 21145847 DOI: 10.1016/j.jhep.2010.08.041]
88. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF. Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol 2011; 54: 497-505 [PMID: 21112656 DOI: 10.1016/j.jhep.2010.07.044]
89. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: New vistas and open questions. Eur J Immunol 2011; 41: 2522-2525 [PMID: 21952810 DOI: 10.1002/eji.201141894]
90. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-1073 [PMID: 19741157 DOI: 10.1189/jlb.0609385]
91. Müller G. Dynamics of plasma membrane microdomains and crosstalk to the insulin signalling cascade. FEBS Lett 2002; 531: 81-87 [PMID: 12401208]
92. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78 [PMID: 14708027 DOI: 10.1038/nrc1256]
93. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612 [PMID: 16423985 DOI: 10.1158/0008-5472.CAN-05-4005]
94. Shirabe K, Mano Y, Muto J, Matono R, Motomura T, Toshima T, Takeishi K, Uchiyama H, Yoshizumi T, Taketomi A, Morita M, Tsujitani S, Sakaguchi Y, Maehara Y. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 2012; 42: 1-7 [PMID: 22116397 DOI: 10.1007/s00595-011-0058-8]
95. Mano Y, Aishima S, Fujita N, Tanaka Y, Kubo Y, Motomura T, Taketomi A, Shirabe K, Maehara Y, Oda Y. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology 2013; 80: 146-154 [PMID: 23364389 DOI: 10.1159/000346196]
96. Li T, Yang Y, Hua X, Wang G, Liu W, Jia C, Tai Y, Zhang Q, Chen G. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett 2012; 318: 154-161 [PMID: 22182446 DOI: 10.1016/j.canlet.2011.12.020]
97. Cheng JT, Deng YN, Yi HM, Wang GY, Fu BS, Chen WJ, Liu W, Tai Y, Peng YW, Zhang Q. Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6- mediated STAT3 activation. Oncogenesis 2016; 5: E198 [PMID: 26900950 DOI: 10.1038/oncsis.2016.7]
98. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31: 220-227 [PMID: 20538542 DOI: 10.1016/j.it.2010.04.002]
99. Chen CH, Kuo LM, Chang Y, Wu W, Goldbach C, Ross MA, Stolz DB, Chen L, Fung JJ, Lu L, Qian S. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology 2006; 44: 1171-1181 [PMID: 17058227 DOI: 10.1002/hep.21379]
100. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-3029 [PMID: 20008522 DOI: 10.1084/jem.20090847]
101. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124: 1061-1065 [PMID: 10888784 DOI: 10.1043/0003-9985(2000) 1242.0.CO;2]
102. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 68-77 [PMID: 9657098 DOI: 10.1002/hep.510280111]
103. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, Housset C, Rosmorduc O. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002; 35: 1010-1021 [PMID: 11981751 DOI: 10.1053/jhep.2002.32524]
104. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, Vizzutti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42: 1339-1348 [PMID: 16317688 DOI: 10.1002/hep.20965]
105. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, Kodama Y, Miura K, Ikai I, Uemoto S, Brenner DA. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008; 135: 1729-1738 [PMID: 18823985 DOI: 10.1053/j.gastro.2008.07.065]
106. Ankoma-Sey V, Wang Y, Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 2000; 31: 141-148 [PMID: 10613739 DOI: 10.1002/hep.510310122]
107. Gressner AM, Lahme B, Meurer SK, Gressner O, Weiskirchen R. Variable expression of cystatin C in cultured trans-differentiating rat hepatic stellate cells. World J Gastroenterol 2006; 12: 731-738 [PMID: 16521186]
108. Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cravanzola C, Compagnone A, Colombatto S, Marra F, Pinzani M, Parola M. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007; 170: 1942-1953 [PMID: 17525262]
109. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998; 29: 986-991 [PMID: 9744316]
110. Jo M, Nishikawa T, Nakajima T, Okada Y, Yamaguchi K, Mitsuyoshi H, Yasui K, Minami M, Iwai M, Kagawa K, Itoh Y, Yoshikawa T. Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroenterol 2011; 46: 809-821 [PMID: 21452000 DOI: 10.1007/s00535-011-0392-z]
111. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994; 58: 50-56 [PMID: 8014015]
112. Ding W, You H, Dang H, LeBlanc F, Galicia V, Lu SC, Stiles B, Rountree CB. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 2010; 52: 945-953 [PMID: 20564331 DOI: 10.1002/hep.23748]
113. Elrick LJ, Leel V, Blaylock MG, Duncan L, Drever MR, Strachan G, Charlton KA, Koruth M, Porter AJ, Wright MC. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells-A potential mechanism for targeting liver anti-fibrotic therapeutics. J Hepatol 2005; 42: 888-896 [PMID: 15885360 DOI: 10.1016/j.jhep.2005.01.028]
114. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, Takimoto R, Takada K, Miyanishi K, Matsunaga T, Takayama T, Niitsu Y. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008; 26: 431-442 [PMID: 18376398 DOI: 10.1038/nbt1396]
115. Osawa Y, Oboki K, Imamura J, Kojika E, Hayashi Y, Hishima T, Saibara T, Shibasaki F, Kohara M, Kimura K. Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/ß-Catenin Reduces Liver Fibrosis in Mice. EBioMedicine 2015; 2: 1751-1758 [PMID: 26870800 DOI: 10.1016/j.ebiom.2015.10.010]
116. Kubo N, Saito R, Hamano K, Nagasawa M, Aoki F, Takei I, Umezawa K, Kuwano H, Kojima I. Conophylline suppresses hepatic stellate cells and attenuates thioacetamide-induced liver fibrosis in rats. Liver Int 2014; 34: 1057-1067 [PMID: 24119135 DOI: 10.1111/liv.12328]
117. Weng TC, Shen CC, Chiu YT, Lin YL, Huang YT. Effects of armepavine against hepatic fibrosis induced by thioacetamide in rats. Phytother Res 2012; 26: 344-353 [PMID: 21717514 DOI: 10.1002/ptr.3539]
118. Patella S, Phillips DJ, Tchongue J, de Kretser DM, Sievert W. Follistatin attenuates early liver fibrosis: Effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G137-G144 [PMID: 16123203 DOI: 10.1152/ajpgi.00080.2005]
119. Tsai MK, Lin YL, Huang YT. Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. Toxicol Appl Pharmacol 2010; 242: 155-164 [PMID: 19822164 DOI: 10.1016/j.taap.2009.10.002]
120. Wang X, Ikejima K, Kon K, Arai K, Aoyama T, Okumura K, Abe W, Sato N, Watanabe S. Ursolic acid ameliorates hepatic fibrosis in the rat by specific induction of apoptosis in hepatic stellate cells. J Hepatol 2011; 55: 379-387 [PMID: 21168456 DOI: 10.1016/j.jhep.2010.10.040]
121. Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJ, Iredale JP, Mann DA. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121: 685-698 [PMID: 11522753]
122. Shu JC, He YJ, Lv X, Ye GR, Wang LX. Curcumin prevents liver fibrosis by inducing apoptosis and suppressing activation of hepatic stellate cells. J Nat Med 2009; 63: 415-420 [PMID: 19554395 DOI: 10.1007/s11418-009-0347-3]
123. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 1163-1174 [PMID: 9486988 DOI: 10.1172/JCI992]
124. Fischer R, Schmitt M, Bode JG, Häussinger D. Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology 2001; 120: 1212-1226 [PMID: 11266385 DOI: 10.1053/gast.2001.23260]
125. Kim JY, Kim KM, Nan JX, Zhao YZ, Park PH, Lee SJ, Sohn DH. Induction of apoptosis by tanshinone I via cytochrome c release in activated hepatic stellate cells. Pharmacol Toxicol 2003; 92: 195-200 [PMID: 12753423]
126. Ward SC, Waxman S. Fibrolamellar carcinoma: A review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis 2011; 31: 61-70 [PMID: 21344351 DOI: 10.1055/s-0031-1272835]
127. Riehle KJ, Yeh MM, Yu JJ, Kenerson HL, Harris WP, Park JO, Yeung RS. mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. Mod Pathol 2015; 28: 103-110 [PMID: 24925055 DOI: 10.1038/modpathol.2014.78]
128. Huang L, Xu AM, Liu S, Liu W, Li TJ. Cancer-associated fibroblasts in digestive tumors. World J Gastroenterol 2014; 20: 17804-17818 [PMID: 25548479 DOI: 10.3748/wjg.v20.i47.17804]
129. Steinbichler TB, Metzler V, Pritz C, Riechelmann H, Dudas J. Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells. Oncotarget 2016; 7: 2508-2518 [PMID: 26497215 DOI: 10.18632/oncotarget.6210]
130. Tanaka K, Miyata H, Sugimura K, Fukuda S, Kanemura T, Yamashita K, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis 2015; 36: 894-903 [PMID: 26026166 DOI: 10.1093/carcin/bgv067]
131. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273 [PMID: 19262571 DOI: 10.1038/nrc2620]
132. Hawsawi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al- Tweigeri T, Ajarim D, Alaiya A, Dermime S, Aboussekhra A. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res 2008; 68: 2717-2725 [PMID: 18413739 DOI: 10.1158/0008-5472.CAN-08-0192]
133. Amornsupak K, Insawang T, Thuwajit P, O-Charoenrat P, Eccles SA, Thuwajit C. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer 2014; 14: 955 [PMID: 25512109 DOI: 10.1186/1471-2407-14-955]
134. Yan H, Guo BY, Zhang S. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling. Biochem Biophys Res Commun 2016; 470: 947-954 [PMID: 26826383 DOI: 10.1016/j.bbrc.2016.01.131]